Agence Française de Sécurité Sanitaire des Aliments, Unité Antibiorésistance et Virulence Bactérienne, Lyon, France.
Antimicrob Agents Chemother. 2010 Mar;54(3):1140-5. doi: 10.1128/AAC.00915-09. Epub 2010 Jan 11.
Streptococcus uberis is an environmental pathogen commonly causing bovine mastitis, an infection that is generally treated with penicillin G. No field case of true penicillin-resistant S. uberis (MIC > 16 mg/liter) has been described yet, but isolates presenting decreased susceptibility (MIC of 0.25 to 0.5 mg/liter) to this drug are regularly reported to our laboratory. In this study, we demonstrated that S. uberis can readily develop penicillin resistance in laboratory-evolved mutants. The molecular mechanism of resistance (acquisition of mutations in penicillin-binding protein 1A [PBP1A], PBP2B, and PBP2X) was generally similar to that of all other penicillin-resistant streptococci described so far. In addition, it was also specific to S. uberis in that independent resistant mutants carried a unique set of seven consensus mutations, of which only one (Q(554)E in PBP2X) was commonly found in other streptococci. In parallel, independent isolates from bovine mastitis with different geographical origins (France, Holland, and Switzerland) and presenting a decreased susceptibility to penicillin were characterized. No mosaic PBPs were detected, but they all presented mutations identical to the one found in the laboratory-evolved mutants. This indicates that penicillin resistance development in S. uberis might follow a stringent pathway that would explain, in addition to the ecological niche of this pathogen, why naturally occurring resistances are still rare. In addition, this study shows that there is a reservoir of mutated PBPs in animals, which might be exchanged with other streptococci, such as Streptococcus agalactiae, that could potentially be transmitted to humans.
停乳链球菌是一种环境病原体,常引起奶牛乳腺炎,通常用青霉素 G 治疗。虽然尚未描述过真正耐青霉素的停乳链球菌(MIC>16 毫克/升)的田间病例,但我们实验室经常报告对该药物敏感性降低(MIC 为 0.25 至 0.5 毫克/升)的分离株。在这项研究中,我们证明了停乳链球菌可以在实验室进化的突变体中轻易产生青霉素耐药性。耐药性的分子机制(青霉素结合蛋白 1A(PBP1A)、PBP2B 和 PBP2X 的突变获得)通常与迄今为止描述的所有其他青霉素耐药性链球菌相似。此外,它也与停乳链球菌特异性相关,即独立的耐药突变体携带一套独特的七个共识突变,其中只有一个(PBP2X 中的 Q(554)E)在其他链球菌中常见。同时,还对来自法国、荷兰和瑞士等不同地理来源的具有不同青霉素敏感性的奶牛乳腺炎的独立分离株进行了特征描述。未检测到镶嵌型 PBPs,但它们都具有与实验室进化突变体中发现的突变相同的突变。这表明停乳链球菌的青霉素耐药性发展可能遵循一种严格的途径,这除了可以解释该病原体的生态位外,还可以解释为什么自然发生的耐药性仍然很少见。此外,这项研究表明,动物体内存在突变型 PBPs 的储备库,这些储备库可能与其他链球菌(如无乳链球菌)交换,这些链球菌可能会传播给人类。